

Peter R Carroll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2915323/publications.pdf>

Version: 2024-02-01

28
papers

2,757
citations

471509

17
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

3643
citing authors

#	ARTICLE	IF	CITATIONS
1	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 173, 1938-1942.	0.4	592
2	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>European Urology</i> , 2014, 66, 550-560.	1.9	553
3	The CAPRA score. <i>Cancer</i> , 2011, 117, 5039-5046.	4.1	359
4	Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. <i>Journal of the National Cancer Institute</i> , 2009, 101, 878-887.	6.3	287
5	Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. <i>Cancer Research</i> , 2011, 71, 3889-3895.	0.9	241
6	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	1.6	162
7	Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. <i>International Journal of Cancer</i> , 2012, 131, 201-210.	5.1	91
8	Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 712-721.	4.7	61
9	Transpacific variation in outcomes for men treated with primary androgen deprivation therapy (ADT) for prostate cancer. <i>BJU International</i> , 2016, 117, 102-109.	2.5	57
10	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.	1.9	55
11	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2021, 39, 2284-2293.	1.6	54
12	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2031349.	5.9	41
13	Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 386-394.	5.4	32
14	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. <i>European Urology</i> , 2019, 76, 268-272.	1.9	28
15	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. <i>European Urology</i> , 2020, 78, 335-344.	1.9	28
16	Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. <i>Journal of Medical Internet Research</i> , 2020, 22, e19238.	4.3	25
17	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. <i>Clinical Cancer Research</i> , 2014, 20, 5302-5310.	7.0	19
18	A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. <i>BMC Cancer</i> , 2020, 20, 820.	2.6	14

#	ARTICLE	IF	CITATIONS
19	Natural language processing systems for pathology parsing in limited data environments with uncertainty estimation. <i>JAMIA Open</i> , 2020, 3, 431-438.	2.0	10
20	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 1216-1221.	0.4	9
21	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11257.	1.0	9
22	Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 690-693.	3.9	8
23	Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. <i>Urology</i> , 2019, 131, 157-165.	1.0	7
24	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. <i>JCO Precision Oncology</i> , 2021, 5, 710-725.	3.0	6
25	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. <i>European Urology</i> , 2021, 79, 141-149.	1.9	4
26	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2
27	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. <i>Prostate</i> , 2021, 81, 1009-1017.	2.3	2
28	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. <i>Urology</i> , 2021, , .	1.0	1